Drugs that inhibit the protein expressed by a mutated form of the KRAS gene might soon be approved, but cancer cells often develop additional mutations that make them resist such targeted drugs. Investigators have identified some of these mutations in a patient and strategies to overcome them.
Departments, Centers, & Programs:
55 Fruit Street
Boston, MA 02114-2696
- MD, Harvard Medical School
- MPH, Harvard T. H Chan School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Dana Farber Cancer Institute
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research focuses on tumor genetics and targeted therapy in lung cancer, and I lead clinical trials of novel agents in lung cancer.
- Press Release
- Sep | 8 | 2020
Clinical trial finds targeted drug effective in patients who have lung cancer with certain gene mutations
A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial.
- Jul | 7 | 2020
Dr. Rebecca Heist and Casandra McIntyre, RN discuss what clinical trials are and why they are important. Learn how clinical trials are benefitting patients and how we are keeping enrollees safe.